Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
HOME > COMMENTARY
COMMENTARY
-
Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment
March 4, 2019
-
Restructuring, Divestment Progress in Wake of Drug Pricing Overhaul
February 20, 2019
-
2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
January 11, 2019
-
LDP Draws Up Tax Reform Outline, Revamps Credits for R&D Expenses
December 17, 2018
-
After Thumbs-Up Given to Shire Buy, Weber’s Leadership Will Now Be Put to Test
December 12, 2018
-
Does Dissolution of Japan Vaccine Signal Demise of Model in Vaccine Industry Vision, or Will a Second Round of JV Take Place?
November 27, 2018
-
There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
August 3, 2018
-
Astellas/Daiichi Sankyo Showdown Looms as Their FLT3 Inhibitors Near Approval
July 12, 2018
-
LDP Heavyweights on Guard for Push to Scrap Coverage for Patch Medications
July 5, 2018
-
Kudos to MHLW for Creating New Confab, but 1st Meeting Stirs Industry Frustration
May 30, 2018
-
Japan Trains Sight on CEA as Centerpiece of This Year’s Cost Containment Efforts
April 23, 2018
-
With Drug Price Cuts Done, MHLW Now Running Ministry-Wide Initiative to Shave Prescriptions
April 4, 2018
-
Will Drug Makers Move to Pull Plug on Off-Patent Brands under “G1” Scheme?
March 12, 2018
-
With CiCLE Program Entering 2nd Year, AMED Should Release More Information on Grant Program
February 28, 2018
-
Chuikyo Moving toward Conclusion on Issue of Insurance Coverage for Heparinoid Drugs
January 15, 2018
-
Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
December 28, 2017
-
Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
-
With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
October 10, 2017
-
Epigenetic Drug Discovery Efforts Expanding, with Solid Cancers Now Being Targeted
September 1, 2017
-
MHLW Panel Elaborating Rules for Clinical Research Law, “Scholarship Donations” to Be a Major Focus
August 21, 2017
ページ
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…